# Development of Mitochondria-Targeted PARP Inhibitors

## TL;DR

Scientists developed new PARP inhibitors that target mitochondria, showing improved cancer cell killing and selectivity over healthy cells.

## Contribution

The paper introduces mitochondria-targeted PARP inhibitors with enhanced anticancer potency and selectivity.

## Key findings

- Phosphonium conjugates retained potent PARP1 inhibition comparable to existing drugs.
- Compounds 2d and 6c showed strong cardiolipin binding and increased cytotoxicity in BRCA1-deficient cancer cells.
- These conjugates exhibited lower toxicity in non-malignant cardiomyocytes, indicating better selectivity.

## Abstract

PARP inhibitors are a clinically validated class of anticancer therapeutics that exploit synthetic lethality to target homologous recombination-deficient tumors, such as those carrying BRCA1/2 mutations. Nevertheless, the rational design of mitochondria-targeted PARP inhibitors capable of selective mitochondrial accumulation and organelle-specific PARP modulation remains an unresolved objective. To enable organelle-specific modulation of PARP activity, we synthesized a series of trialkyl(aryl)phosphonium conjugates of olaparib and rucaparib designed to target mitochondria by cardiolipin binding. Their activity was evaluated by PARP1 inhibition, cardiolipin affinity, and cytotoxicity in BRCA1-deficient HCC1937 breast cancer cells and non-malignant H9C2 cardiomyocytes. All conjugates retained potent PARP1 inhibition (IC50 = 3.4–17 nM), comparable to the parent drugs. Several derivatives, particularly compounds 2d and 6c, exhibited strong cardiolipin binding (EC50 = 12.99 µM and 6.77 µM, respectively) and significantly enhanced cytotoxicity in HCC1937 cells (IC50 = 0.93 and 2.01 µM), outperforming olaparib and rucaparib. Notably, cytotoxicity toward H9C2 cells was lower, indicating a favorable selectivity profile. Phosphonium conjugation preserves PARP1 inhibitory activity while conferring mitochondrial targeting and enhanced anticancer potency. These findings support the development of mitochondria-targeted PARP inhibitors as a next-generation therapeutic strategy with the potential to improve efficacy and overcome resistance in HR-deficient tumors.